Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $213.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer | Jul 27 '26 | Sale | $20.00 | 1,100 | $22,000 | 2,711,198 | Jul 29 04:10 PM |
| Reich Kristian | Chief Scientific Officer | Jul 21 '26 | Sale | $20.02 | 50,000 | $1,001,000 | 2,714,746 | Jul 23 04:05 PM |
| Reich Kristian | Chief Scientific Officer | Jul 22 '26 | Sale | $20.00 | 2,448 | $48,960 | 2,712,298 | Jul 23 04:05 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.